These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23033257)

  • 21. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 22. National adverse drug reaction reporting. 1984-1989.
    Faich GA
    Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 25. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA is gold standard of review.
    Leahey MB
    BMJ; 2010 Dec; 341():c7004. PubMed ID: 21139000
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA advisory panel voices persistent safety concerns.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):439. PubMed ID: 16595778
    [No Abstract]   [Full Text] [Related]  

  • 28. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA proposes higher fees for drug approvals to cover postmarketing surveillance.
    Tanne JH
    BMJ; 2007 Jan; 334(7586):177. PubMed ID: 17255596
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
    Lexchin J
    CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610
    [No Abstract]   [Full Text] [Related]  

  • 33. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
    MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M
    JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controversies in adverse drug reaction reporting.
    Juergens JP
    Am J Hosp Pharm; 1990 Jan; 47(1):76-7. PubMed ID: 2301428
    [No Abstract]   [Full Text] [Related]  

  • 37. A drug is not a drug is not a drug: a commentary.
    Struijker Boudier HA
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):437-8. PubMed ID: 12426926
    [No Abstract]   [Full Text] [Related]  

  • 38. Communicating the risks of medicines: time to move forward.
    Dal Pan GJ
    Med Care; 2012 Jun; 50(6):463-5. PubMed ID: 22581011
    [No Abstract]   [Full Text] [Related]  

  • 39. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED; Ciociola AA; Kulkarni PM;
    Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
    [No Abstract]   [Full Text] [Related]  

  • 40. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
    Woodcock J
    FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.